Full Press Release Details
NuCana Announces Proposed Public Offering of American Depositary Shares
Edinburgh, United Kingdom, September 16, 2020 (GLOBE NEWSWIRE) NuCana plc, a clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary Shares ( ADSs ). Each ADS represents one ordinary share of NuCana. In addition, NuCana
expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by
NuCana. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Jefferies, Cowen, William Blair, and Truist Securities are acting as joint book-running managers for the offering.
The securities are being offered pursuant to a registration statement on Form F-3 which has been filed with the U.S. Securities and Exchange Commission (the
SEC ) and was declared effective on October 22, 2018. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. Copies of the preliminary
prospectus supplement related to this offering and the accompanying prospectus will be filed with the SEC and will be available on the SEC s website at www.sec.gov and may be obtained, when available, by contacting Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by e-mail at
Prospectus_Department@Jefferies.com, or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, email: PostSaleManualRequests@broadridge.com, telephone:
1-833-297-2926, or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com, or Truist Securities, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus
Department; email: TruistSecurities.prospectus@Truist.com. For the avoidance of doubt, such prospectus will not constitute a prospectus for the purposes of the Prospectus Regulation (as defined below) and will not have been
reviewed by any competent authority in any EEA member state or the United Kingdom.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or
For readers in the European Economic Area (EEA) and the United Kingdom
In any EEA Member State and the United Kingdom (a Relevant State ), this communication is only addressed to and directed at qualified
investors in that Relevant State within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129).
Further notice for readers in the United Kingdom
There will be no offer of ADSs to the public in the United Kingdom. This communication, in so far as it constitutes an invitation or inducement to enter into
investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ( FSMA )) in connection with the securities which are the subject of the offering described in this press release or otherwise,
is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ( Investment professionals ) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order ) or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ( High net worth companies, unincorporated
associations etc. ) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as relevant persons ). The ADSs are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This
communication does not contain an offer or constitute any part of an offer to the public within the meaning of ss. 85 and 102B of FSMA or otherwise.
NuCana is a clinical-stage
biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and
safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.
Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana s robust pipeline
includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil,
respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase
II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I
study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel
nucleoside analog (3 -deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the Company ). All statements other than statements of historical fact contained in this press
release are forward-looking statements, including statements
regarding the anticipated final terms including the amount of ADSs the Company intends to sell, timing and completion of the proposed offering. In some cases, you can identify forward-looking
statements by terminology such as may, will, should, expects, plans, anticipates, believes, estimates, predicts, potential or
continue or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company s actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth
in the Risk Factors section of the Company s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ( SEC ) on
March 10, 2020, subsequent reports that the Company files with the SEC and the preliminary prospectus supplement related to this offering. Forward-looking statements represent the Company s beliefs and assumptions only as of the date of
this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the
Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to
changes in its expectations.
For more information, please contact:
Chief Executive Officer
Westwicke, an ICR Company